In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.
Breast Cancer Targets
The FDA has approved ribociclib in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.
Adding ribociclib, a CDK4/6 inhibitor, to letrozole significantly improved progression-free survival in postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.
OPT-822/821 vaccination did not show any improvement in progression-free survival as maintenance therapy compared with placebo for metastatic breast cancer. But in those patients who had an immune response, the vaccine did appear to show activity.
Heavily pretreated women with metastatic breast cancer had significant improvements in progression-free survival and overall response rate when treated with the combination of utidelone plus capecitabine compared with capecitabine alone.
The investigational biosimilar MYL-1401O has comparable efficacy and safety to the FDA-approved trastuzumab in metastatic HER2-positive breast cancer.
In this interview we discuss results of the PlanB trial, which showed that use of the 21-gene recurrence score, Oncotype DX, can identify patients with early breast cancer who likely do not need chemotherapy.
In this interview we discuss research into cancer vaccines and checkpoint inhibitors for the treatment of breast cancer.
The FDA has expanded the indication for palbociclib (Ibrance), to be used in combination with fulvestrant in women with HR-positive, HER2-negative advanced breast cancer.
ASCO has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer.